Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Howe, J. R.
Right arrow Articles by Scott-Conner, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Howe, J. R.
Right arrow Articles by Scott-Conner, C.
Related Collections
Right arrow Other Malignancies
Annals of Surgical Oncology 8:496-508 (2001)
© 2001 Society of Surgical Oncology

ORIGINAL ARTICLES

Small Bowel Sarcoma: Analysis of Survival From the National Cancer Data Base

James R. Howe, MD, Lucy H. Karnell, PhD and Carol Scott-Conner, MD, PhD

From the Departments of Surgery (JRH), Otolaryngology (LHK), and Surgery (CS-C), University of Iowa College of Medicine, Iowa City, Iowa.

Correspondence: Address correspondence and reprint requests to: James R. Howe, MD, Department of Surgery, University of Iowa College of Medicine, 200 Hawkins Drive, Iowa City, IA 52242; Fax: 319-356-9378; E-mail: james-howe{at}uiowa.edu

Background: Small bowel sarcomas (SBS) are rare, accounting for 10% of small bowel cancers. As a result, few studies of SBS have had enough patients to accurately define their natural history and to determine the factors that have an impact on patient survival. The objective of this study was to examine patient and tumor factors in SBS and to determine prognostic factors for disease-specific survival (DSS) using the National Cancer Data Base.

Methods: Data from the National Cancer Data Base for patients diagnosed with primary SBS between 1985 and 1995 were analyzed. The {chi}2 statistic was used to determine significant differences between groups of patient, tumor, and treatment factors. DSS was calculated for patients diagnosed between 1985 and 1990. Significant differences in survival were determined using the Wilcoxon statistic for univariate analyses and by Cox regression in multivariate analyses.

Results: Of 14,253 small bowel tumors diagnosed between 1985 and 1995, sarcomas represented 10.1%. Overall, 5-year DSS was 38.9%, with a median survival of 34.1 months (n = 590). By univariate analysis, patient age, sex, tumor size, tumor grade, histologic type, general summary stage, nodal status, and whether cancer-directed surgery was performed were significantly correlated with DSS. In multivariate analysis, tumor size <5 cm, leiomyosarcoma histology, and localized disease were found to be significant favorable prognostic factors for DSS.

Conclusions: SBS are rare tumors that are challenging in terms of their histopathologic classification, grading, and staging. Patients with SBS were treated predominantly by surgery, with a minority receiving adjuvant therapy. Tumor size, histologic type, and general summary stage were independent prognostic factors for 5-year DSS in patients with SBS, which is improved relative to 5-year DSS seen in patients with small bowel adenocarcinoma.

Key Words: Small bowel • Gastrointestinal sarcoma • National Cancer Data Base • Disease-specific survival






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the Society of Surgical Oncology.